The financing round was led by Concord Health Partners, with AlbaCore Capital Group and Hambro Perks also contributing. The latest haul follows a $125 million raise that the company announced in October.
ViVE 2022, powered by HLTH and CHIME, will convene top thought leaders who are shaping tech-enabled healthcare and addressing key issues in digital health innovation. Save $150 with code medcity150!
Andrew Bott, Director of Talent Acquisition in EMEA & APAC countries at Medidata, shared his insights on hiring trends in this sector, in response to emailed questions.
By Ramon Rivera Thursday, February 17, 2022 5:06 PM
Hospital leaders must meet or exceed patients' expectations for a pleasant, predictable registration experience to maintain a competitive advantage. Consumers don't see how real-time patient tracking helps departments communicate better, but it has an outsized effect on their experience.
By Frank Vinluan Thursday, February 17, 2022 4:38 PM
Yumanity's corporate restructuring means the biotech is now exploring "strategic alternatives" that could include a sale of the company or its assets. The biotech's lead drug candidate is an experimental Parkinson's disease drug currently in Phase 1 testing.
By Benjamin Marcus Thursday, February 17, 2022 4:32 PM
During my 36-year-old brother's terminal stay in the ICU, I discovered a dire need for a more comprehensive approach to critical care. The more he relied on this large, corporate hospital system to keep him healthy and happy, the clearer it became that no matter how highly-ranked or well-funded it was, this hospital did not possess the flexibility, agility, or progressive thinking it needed to confront cases like his.
By Emma Bardin Thursday, February 17, 2022 2:24 PM
Liana Douillet Guzmán, who takes over as CEO at Folx Health, explained how the digital platform offers virtual care as well as the option to have medications shipped directly to patients' homes.
By Frank Vinluan Thursday, February 17, 2022 12:47 PM
Several biotech companies are rising to the challenge of developing small molecules to drug RNA. Remix Therapeutics is joining the chase, but its different approach has drawn the interest of Johnson & Johnson, which has inked an R&D alliance spanning cancer and immunology.
Leverage the Knowledge Hub on MedCity News to elevate thought leadership and awareness and generate leads for your sales team – ONLY paying for qualified leads..
No comments